Skip to main content
SpringerLink
Log in

Molecular mechanisms of antiestrogen action in breast cancer

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The success of antiestrogen therapy to treat all stages of breast cancer, and the evaluation of tamoxifen as a preventive for breast cancer in normal women, have focused attention on the molecular mechanisms of antiestrogen action and mechanisms of drug resistance. The overall goal of research is to enhance current therapies and to develop new approaches for breast cancer treatment and prevention. Recent studies show that tamoxifen and the new pure antiestrogens appear to have different mechanisms of action: tamoxifen and related compounds cause a change in the folding of the steroid binding domain that prevents gene activation whereas the pure antiestrogens cause a reduced interaction at response elements and cause a rapid loss of receptor complexes. Tamoxifen treatment produces changes in the cellular and circulating levels of growth factors that could influence both receptor negative or receptor positive tumor growth and the metastatic potential of a tumor. These events may explain the survival advantage observed with tamoxifen therapy. However, the current therapeutic challenge is to avoid drug resistance during long-term tamoxifen therapy. Numerous explanations for drug resistance to tamoxifen have been suggested, including elevated estrogen levels, increased tumor antiestrogen binding sites, receptor mutations, and impaired signal transduction. However, it is probable that multiple mechanisms evolve to facilitate tumor survival. Most importantly, current research is examining mechanisms responsible for the beneficial actions of tamoxifen on bones and lipids as well as the potentially deleterious effects of tamoxifen on liver and endometrial carcinogenesis and retinopathy. The urgent need to understand antiestrogenic drug mechanisms and toxicity is being facilitated by the application of the technology developed for basic molecular biology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Chapter © 2017

References

  1. Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127–205, 1985

    Google Scholar 

  2. Sunderland MC, Osborne CK: Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 9: 1285–1297, 1991

    Google Scholar 

  3. Early Breast Cancer Trialists Collaborative Group: systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 1–15, 71-85, 1992

    Google Scholar 

  4. Fisher B, Costantino J, Redmond C, and other members of NSABP: a randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 320: 479–484, 1989

    Google Scholar 

  5. Powles TJ, Tillyer CR, Jones AL, Ashley SF, Treleaven J, Davey JB, McKinna JA: Prevention of breast cancer with tamoxifen - an update of the Royal Marsden Hospital pilot program. Eur J Cancer 26: 680–684, 1990

    Google Scholar 

  6. Fisher B: The evolution of paradigms for management of breast cancer: a personal perspective. Cancer Res 52: 2371–2383, 1992

    Google Scholar 

  7. Jordan VC: A current view of tamoxifen for treatment and prevention of breast cancer. Br J Pharmacol 110: 507–517, 1993

    Google Scholar 

  8. Valavaara R, Pyrrhonen S, Heikkinen M, Rissanen P, Blanco G, Tholix E, Nordman E, Taskinen P, Holsti L, Hajba A: Toremifene, a new antiestrogenic compound for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 24: 785–790, 1988

    Google Scholar 

  9. Bruning PF: Droloxifene, a new antiestrogen in postmenopausal advanced breast cancer: preliminary results in a double-blind dose finding Phase II trial. Eur J Cancer 28A: 1404–1407, 1992

    Google Scholar 

  10. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867–3873, 1991

    Google Scholar 

  11. Wakeling AE, Bowler J: Steroidal pure antioestrogens. J Endocrinol 112: R7-R10, 1987

    Google Scholar 

  12. Gottardis MM, Jiang SY, Jeng MH, Jordan VC: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49: 4090–4093, 1989

    Google Scholar 

  13. Gottardis MM, Ricchio ME, Satyaswaroop PG, Jordan VC: Effect of steroidal and non-steroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 50: 3189–3192, 1990

    Google Scholar 

  14. DeFriend D, Blamey R, Masel R, Anderson E, Nicholson R, Robertson J, Bundred N, Sanders C, Dowsett M, Baum M, Walton P, Sutcliffe F, Howell A: Phase I clinical trial of the novel pure antioestrogen ICI 182,780 in women with primary breast cancer. Proc ASCO (Orlando, FL) Vol 12, abst 43, 1993

  15. Jordan VC: A therapeutic withdrawal can make a strategic advance (editorial). Ann Oncol 3: 587, 1992

    Google Scholar 

  16. Jordan VC, Collins MM, Rowsby L, Prestwich G: A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75: 305–316, 1977.

    Google Scholar 

  17. Jordan VC, Dix CJ, Naylor KE, Prestwich G, Rowsby L: Non-steroidal antioestrogens: their biological effects and potential mechanisms of action. J Toxicol Environ Health 4: 364–390, 1978

    Google Scholar 

  18. Jordan VC, Allen KE: Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16: 239–251, 1980

    Google Scholar 

  19. Coezy E, Borgna JL, Rochefort H: Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42: 317–323, 1982

    Google Scholar 

  20. Korenman SG: Relation between estrogen inhibiting activity and binding to cytosol of rabbit and human uterus. Endocrinology 87: 1119–1123, 1970

    Google Scholar 

  21. Lippman ME, Bolan G: Oestrogen-responsive human breast cancer in long-term tissue culture. Nature (Lond) 256: 592–595, 1975

    Google Scholar 

  22. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS: Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83: 2496–2500, 1986

    Google Scholar 

  23. Lieberman ME, Maurer RA, Gorski J: Estrogen control of prolactin synthesisin vitro. Proc Natl Acad Sci USA 75: 5946–5950, 1978

    Google Scholar 

  24. Lieberman ME, Jordan VC, Fritsch M, Santos MA, Gorski J: Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogensin vitro. J Biol Chem 258: 4734–4740, 1983

    Google Scholar 

  25. Lieberman ME, Gorski J, Jordan VC: An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogensin vitro. J Biol Chem 258: 4741–4745, 1983

    Google Scholar 

  26. Bindall RD, Katzenellenbogen JA: Bis (4-hydroxyphenyl) [2-(phenoxysulfonyl) phenyl]methane: isolation and structure elucidation of a novel estrogen from commercial preparations of phenol red (phenolsulfonphthalein). J Med Chem 31: 1978–1985, 1988

    Google Scholar 

  27. Welshons WV, Wolf MF, Murphy CS, Jordan VC: Estrogenic activity of phenol red. Mol Cell Endo 57: 169–178, 1988

    Google Scholar 

  28. Green S, Walter P, Kumar V, Krust A, Barnet JM, Argos P, Chambon P: Human oestrogen receptor cDNA: sequence, expression and homology to v-erb A. Nature (Lond) 320: 134–139, 1986

    Google Scholar 

  29. Jordan VC, Koerner S: Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 11: 205–206, 1975

    Google Scholar 

  30. Jordan VC: Biochemical pharmacology of antiestrogen action. Pharm Rev 36: 245–276, 1984

    Google Scholar 

  31. Jordan VC, Murphy CS: Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 11: 578–610, 1991

    Google Scholar 

  32. Rochefort H, Borgna JL, Evans E: Cellular and molecular mechanisms of action of antiestrogens. J Steroid Biochem 19: 69–74, 1983

    Google Scholar 

  33. Garcia M, Greene GL, Rochefort H, Jensen EV: Effect of antibodies to estrogen receptors on the binding of [3H] labeled antiestrogens and androstenedione in the uterus. Endocrinology 110: 1355–1360, 1982

    Google Scholar 

  34. Tate AC, Greene GL, DeSombre ER, Jensen EV, Jordan VC: Differences between estrogen- and antiestrogen- estrogen receptor complexes identified with an antibody raised against the estrogen receptor. Cancer Res 44: 1012–1018, 1984

    Google Scholar 

  35. Martin PM, Berthois Y, Jensen EV: Binding of antiestrogens exposes an occult antigenic determinant in the human estrogen receptor. Proc Natl Acad Sci USA 85: 2533–2537, 1988

    Google Scholar 

  36. Allen KE, Clark ER, Jordan VC: Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure activity relationships. Br J Pharmacol 71: 83–91, 1980

    Google Scholar 

  37. Borgna JL, Rochefort H: Hydroxylated metabolites of tamoxifen are formedin vivo and bound to estrogen receptors in target tissues. J Biol Chem 256: 859–868, 1981

    Google Scholar 

  38. Katzenellenbogen BS, Ferguson ER: Antiestrogen action in the uterus: biological ineffectiveness of nuclear bound estradiol after antiestrogen. Endocrinology 97: 1–12, 1975

    Google Scholar 

  39. Jordan VC, Dix CJ, Rowsby L, Prestwich G: Studies on the mechanism of action of the non-steroidal antioestrogen tamoxifen (ICI 46,474) in the rat. Mol Cell Endocrinol 7:177–192, 1977

    Google Scholar 

  40. Jordan VC, Naylor KE: The binding of [3H] oestradiol 17β in the immature rat uterus during the sequential administration of antioestrogens. Br J Pharmacol 65: 167–173, 1979

    Google Scholar 

  41. Metzger D, White JH, Chambon P: The human oestrogen receptor functions in yeast. Nature 334: 31–36, 1988

    Google Scholar 

  42. Jordan VC, Lieberman ME, Cormier E, Koch R, Bagley J, Ruenitz P: Structural requirements for the pharmacological activity of non-steroidal antiestrogensin vitro. Mol Pharm 26: 272–278, 1984

    Google Scholar 

  43. Jordan VC, Lieberman ME: Estrogen-stimulated prolactin synthesisin vitro; classification of agonist, partial agonist, and antagonist actions based on structure. Mol Pharm 26: 279–285, 1984

    Google Scholar 

  44. Jordan VC, Koch R, Langan S, McCague R: Ligand interaction at the estrogen receptor to program antiestrogen action: a study with non-steroidal compoundsin vitro. Endocrinology 122: 1449–1454, 1988

    Google Scholar 

  45. Vegeto E, Allan GF, Schrader WT, Tsai MJ, McDonnell DP, O'Malley BW: The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 69: 703–713, 1992

    Google Scholar 

  46. Fawell SE, White R, Howe S, Sydenham M, Paye M, Parker MG: Inhibition of estrogen receptor-DNA binding by the pure antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87: 6883–6887, 1990

    Google Scholar 

  47. Sabbah M, Gouilleux F, Sola B, Redruith G, Baulieu EE: Structural differences between the hormone and antihormone estrogen receptor complexes bound to the hormone response element. Proc Natl Acad Sci USA 88: 390–394, 1991

    Google Scholar 

  48. Pham TA, Elliston JF, Nawaz Z, McDonnell DP, Tsai MJ, O'Malley BW: Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers. Proc Natl Acad Sci USA 88: 3125–3129, 1991

    Google Scholar 

  49. Gibson MK, Nemmers LA, Beckman WC, Davis VL, Curtis SW, Korach KS: The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129: 2000–2010, 1991

    Google Scholar 

  50. Dauvois S, Danielian PS, White R, Parker MG: Antiestrogen ICI 164, 384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89: 4037–4041, 1992

    Google Scholar 

  51. Bates SE, Davidson NE, Valacrius EM, Freter CE, Dickson RB, Tam JP, Lippman ME: Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol 2: 543–555, 1988

    Google Scholar 

  52. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417–428, 1987

    Google Scholar 

  53. Jeng MH, ten Dijke P, Iwata KK, Jordan VC: Regulation of the levels of three transforming growth factor mRNA's by estrogen and their effects on the proliferation of human breast cancer cells. Mol Cell Endocrinol 97: 115–123, 1993

    Google Scholar 

  54. Arteaga CL, Tandon AK, Von Hoff DD, Osborne CK: Transforming growth factor: potential autocrine growth inhibitor of estrogen receptor negative breast cancer cells. Cancer Res 48: 3898–3904, 1988

    Google Scholar 

  55. Robinson SP, Jordan VC: Antiestrogenic action of toremifene on hormone dependent, independent and heterogeneous breast tumor growth in the athymic mouse. Cancer Res 49: 1758–1762, 1989

    Google Scholar 

  56. Colletta AA, Wakefield LM, Howell FV, Van Roozendaal KE, Danielpour D, Ebbs SR, Sporn MB, Baum M: Antioestrogens induce the secretion of active transforming growth factor from human fetal fibroblasts. Br J Cancer 62: 405–409, 1990

    Google Scholar 

  57. Butta A, MacLennan K, Flanders KC, Sacks NPM, Smith I, McKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M, Colletta AA: Induction of transforming growth factor in human breast cancerin vivo following tamoxifen treatment. Cancer Res 52: 4261–4264, 1992

    Google Scholar 

  58. Noguchi S, Motomura K, Inoji H, Imaoka S, Koyama H: Down regulation of transforming growth factor alpha by tamoxifen in human breast cancer. Cancer 72: 131–136, 1993

    Google Scholar 

  59. Rose DP, Chlebowski RT, Connelly JM, Jones LA, Wynder EL: Effects of tamoxifen adjuvant therapy and a low-fat diet on serum binding proteins and estradiol bioavailability in postmenopausal breast cancer patients. Cancer Res 52: 5386–5390, 1992

    Google Scholar 

  60. Freiss G, Prebois C, Rochefort H, Vignon F: Antisteroidal and anti-growth factor activities of antiestrogens. J Steroid Biochem Mol Biol 37: 777–781, 1990

    Google Scholar 

  61. Pollak MN, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R: Effect of tamoxifen on serum insulin-like growth factor-1 levels in stage 1 breast cancer patients. J Natl Cancer Inst 82: 1693–1697, 1990

    Google Scholar 

  62. Huynh HT, Tetenes E, Wallace L, Pollak MN:In vivo inhibition of insulin-like growth factor 1 gene expression by tamoxifen. Cancer Res 53: 1727–1730, 1993

    Google Scholar 

  63. Gagliardi A, Collins DC: Inhibition of angiogenesis by antiestrogens. Cancer Res 53: 533–535, 1993

    Google Scholar 

  64. Senie RT, Rosen PP, Rhodes P, Lesser ML: Timing of breast cancer excision during the menstrual cycle influences duration of disease free survival. Ann Int Med 115: 337–342, 1991

    Google Scholar 

  65. Friedl A, Gottardis MM, Pink J, Buchler DA, Jordan VC: Enhanced growth of an estrogen receptor negative endometrial adenocarcinoma by estradiol in athymic mice. Cancer Res 49: 4758–4764, 1989

    Google Scholar 

  66. Jordan VC: Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res Treat 15: 125–136, 1990

    Google Scholar 

  67. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC: Alteration of endocrine parameters in premenopausal women with breast cancer during long-term tamoxifen monotherapy. J Natl Cancer Inst 83: 1488–1491, 1991

    Google Scholar 

  68. Sawka CA, Pritchard KI, Paterson DJA, Thompson DB, Skelley WE, Myers RE, Mobbs BG, Malkin A, Meakin JW: Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast cancer. Cancer Res 46: 3152–3156, 1986

    Google Scholar 

  69. Sutherland RL, Murphy LC, Foo MS, Green MD, Whybourne AM, Krozowski ZS: High affinity antioestrogen binding site distinct from the oestrogen receptor. Nature (Lond) 288: 273–275, 1980

    Google Scholar 

  70. Pavlik EJ, Nelson K, Srinivasan S, Powell DE, Kenady DE, DePriest PD, Gallion HH, van Nagell JR Jr: Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity. Cancer Res 52: 4106–4112, 1992

    Google Scholar 

  71. Murphy CS, Meisner LF, Wu SQ, Jordan VC: Characterization of a receptor-negative hormone non-responsive clone derived from T47 D human breast cancer cell line kept under estrogen free conditions. Cancer Res 50: 7285–7292, 1990

    Google Scholar 

  72. Dorssers LCJ, van Agthoven T, Dekker A, van Agthoven TLA, Kok EM: Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site. Mol Endocrinol 7: 870–878, 1993

    Google Scholar 

  73. Osborne CK, Coronado EB, Robinson JP: Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23: 1189–1196, 1987

    Google Scholar 

  74. Gottardis MM, Jordan VC: Development of tamoxifenstimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48: 5183–5187, 1988

    Google Scholar 

  75. Satyaswaroop PG, Zaino RJ, Mortel R: Estrogen-like effects of tamoxifen on human endometrium carcinoma transplanted into nude mice. Cancer Res 44: 4006–4010, 1984

    Google Scholar 

  76. Osborne CK, Coronado E, Allred DC, Weibe VJ, DeGregorio M: Acquired tamoxifen resistance. Correlation with reduced breast cancer tumor levels and isomerization of trans 4-hydroxytamoxifen. J Natl Cancer Inst 83: 1477–1482, 1991

    Google Scholar 

  77. Wiebe VJ, Osborne CK, McGuire WL, DeGregorio M. Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 10: 991–994, 1992

    Google Scholar 

  78. Murphy CS, Langan-Fahey SM, McCague R, Jordan VC: Structure function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen responsive T47D breast cancer cellsin vitro. Mol Pharm 38: 737–743, 1990

    Google Scholar 

  79. Wolf DM, Langan-Fahey SM, Parker CJ, McCague R, Jordan VC: Investigation of the mechanism of tamoxifenstimulated breast tumor growth with non-isomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst 85: 806–812, 1993

    Google Scholar 

  80. Murphy LC, Dotzlaw H: Variant estrogen receptor mRNA species detected in human breast cancer biopsy samples. Mol Endocrinol 3: 687–693, 1989

    Google Scholar 

  81. Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McDonnel DP, Nawaz Z, O'Malley BW, McGuire WL: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51: 105–109, 1991

    Google Scholar 

  82. Fuqua SA, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnel DP, O'Malley BW, Greene GL, McGuire WL: Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 52: 482–486, 1992

    Google Scholar 

  83. Veldscholte J, Ris-Stalpers C, Kulper GGJM, Jenster G, Berrevoets C, Claassen E, Van Rooij HCJ, Trapman J, Bunkmann AO, Mulder E. A mutation in the ligand domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 17: 534–540, 1990

    Google Scholar 

  84. Jiang SY, Jordan VC: Growth regulation of estrogen receptor negative breast cancer cells transfected with complementary DNA's for estrogen receptor. J Natl Cancer Inst 84: 580–591, 1992

    Google Scholar 

  85. Tora L, Mullick A, Metzer D, Ponglikitmongkol M, Park I, Chambon P: The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J 8: 1891–1896, 1989

    Google Scholar 

  86. Jiang SY, Langan-Fahey SM, Stella AL, McCague R, Jordan VC: Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNA's for ER. Mol Endocrinol 6: 2167–2174, 1992

    Google Scholar 

  87. Jiang SY, Parker CJ, Jordan VC: A model to describe how a point mutation of the estrogen receptor alters the structure function relationship of antiestrogens. Breast Cancer Res Treat 26:139–148, 1993

    Google Scholar 

  88. Wolf DM, Jordan VC: The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat (this issue)

  89. Green S, Chambon P: The oestrogen receptor: from perception to mechanism. In: Parker MG (ed) Nuclear Hormone Receptors. Academic Press, London, 1990, pp 15–38

    Google Scholar 

  90. Mullick A, Chambon P: Characterization of the estrogen receptor in two antiestrogen resistant cell lines LY2 and T47D. Cancer Res 50: 333–338, 1990

    Google Scholar 

  91. Jiang SY, Wolf DM, Yingling JM, Chang C, Jordan VC: An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol 90: 77–86, 1992

    Google Scholar 

  92. Jordan VC: Long-term tamoxifen therapy for breast cancer. University of Wisconsin Press, Madison (in press)

  93. Morrow M, Jordan VC: The tamoxifen trial for breast cancer: clinical issues. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer Prevention. Lippincott Healthcare, Philadelphia, 1992, pp 1–12

    Google Scholar 

  94. Williams GM, Iatropoulos HJ, Djordjevic MV, Kaltenberg OP: The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14: 315–317, 1993

    Google Scholar 

  95. Dragan YP, Xu YD, Pitot HC: Tumor promotion as a target for estrogen/antiestrogen effects in rat hepatocarcinogenesis. Prev Med 20: 15–26, 1991

    Google Scholar 

  96. Dragan YP, Fahey SM, Street K, Vaughan J, Jordan VC, Pitot H: Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res Treat (this issue)

  97. Han X, Liehr JG: Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52: 1360–1363, 1992

    Google Scholar 

  98. White INH, de Matteis F, Davis A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, Phillips DH: Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats DBA/d and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13: 2197–2203, 1992

    Google Scholar 

  99. Wanless IR, Medline A: Role of estrogens as promoters of hepatic neoplasia. Lab Invest 46: 313–320, 1982

    Google Scholar 

  100. Prentice RL: Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers. Prev Med 20: 38–46, 1991

    Google Scholar 

  101. Friedl A, Jordan VC: What do we know and what don't we know about tamoxifen in the human uterus. Breast Cancer Res Treat (this issue)

  102. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 82: 1327–1331, 1990

    Google Scholar 

  103. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal, Jordan VC, Feyzi J, DeMets DL: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Int Med 115: 860–864, 1991

    Google Scholar 

  104. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852–856, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Robert H. Lurie Cancer Center, Northwestern University Medical School, 303 East Chicago Avenue Olson Pavillion 8250, 60611-3008, Chicago, IL, USA

    V. Craig Jordan

Authors
  1. V. Craig Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jordan, V.C. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Tr 31, 41–52 (1994). https://doi.org/10.1007/BF00689675

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00689675

Key words

Search

Navigation